New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
Posted inBlood Bone Marrow Crispr (DNA) Developing Countries Drugs (Pharmaceuticals) Food and Drug Administration Genetic Engineering Genetics and Heredity Income Inequality Sickle Cell Anemia Stem Cells Therapy and Rehabilitation Transplants Vertex Pharmaceuticals Inc

New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most

There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.
A Dilemma for Governments: How to Pay for Million-Dollar Therapies
Posted inBrazil Children and Childhood Disabilities Drugs (Pharmaceuticals) Genetic Engineering Genetics and Heredity Medicine and Health Novartis AG Spinal Muscular Atrophy Suits and Litigation (Civil)

A Dilemma for Governments: How to Pay for Million-Dollar Therapies

A wave of transformative but hugely expensive treatments is challenging the budgets of health systems in wealthy nations. Now countries with far fewer resources are wrestling with how to cover the therapies.